Drug Trial Radar · NCT05743881
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months
Last checked: Nov 20, 2026Latest source record: Jun 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
186
Actual
Start
Feb 15, 2023
Primary completion
Aug 31, 2029
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Feb 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 5 months, up to 24 months
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and immunogenicity of mRNA-1365, an mRNA vaccine targeting respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) and mRNA-1345, an mRNA vaccine targeting RSV, in participants aged 5 months to \<24 months.
Conditions
- Respiratory Syncytial Virus
- Human Metapneumovirus
Interventions
mRNA-1345Biological
Sterile liquid for injection
mRNA-1365Biological
Sterile liquid for injection
PlaceboBiological
0.9% sodium chloride (normal saline) solution for injection
NimenrixDrug
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Main Study: Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)Time frame: Up to Day 120 (7 days after each injection)
- Main Study: Number of Participants with Unsolicited Adverse Events (AEs)Time frame: Up to Day 141 (28 days after each injection)
- Main Study: Number of Participants with Medically-Attended Adverse Events (MAAEs)Time frame: Day 1 through Day 730
- Main Study: Number of Participants with Adverse Event of Special Interests (AESIs), Serious Adverse Events (SAEs) and Adverse Events Leading to DiscontinuationTime frame: Day 1 through Day 730
- Part B Extension: Number of Participants with MAAEs, AESIs and SAEsTime frame: Day 1 of the Extension to end of study (EoS) (up to 3 years)
- Part B Extension: Number of Participants with Lower Respiratory Tract Illness (LRTI), Severe LRTI, Very Severe LRTI, and Hospitalizations Associated with RSV or hMPVTime frame: Day 1 of the Extension to EoS (up to 3 years)
Locations
17 sites in 3 countries. Site status is shown where the registry gives one.
Matrix Clinical Research
Los Angeles, California
Meridian Clinical Research
Washington D.C., District of Columbia
DM Clinical Research- River Forest
Melrose Park, Illinois
MedPharmics - Platinum - PPDS
Lafayette, Louisiana
Duke Vaccine and Trials Unit
Durham, North Carolina
Velocity Clinical Research - Providence
Providence, Rhode Island
Palmetto Pediatrics, PA
North Charleston, South Carolina
Vanderbilt Vaccine Research Program
Nashville, Tennessee
CyFair
Houston, Texas
Pediatric Associates
Houston, Texas
Village Pediatrics
Plano, Texas
Pediatric Center
Richmond, Texas
CEVAXIN Avenida Mexico
Panama City, Panama
CEVAXIN 24 de Diciembre
Panama City, Panama
CEVAXIN David
David, Chiriquí Province, Panama
CEVAXIN Chorrera
La Chorrera, Panamá Oeste Province, Panama
Norfolk and Norwich University Hospitals
Norwich, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.